drugset / Trial / NCT04877522
Asciminib Roll-over Study
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a long term safety study for patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment
Timeline
- Start
- 2022-08-30
- Primary completion
- 2030-08-30
- Completion
- 2030-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Asciminib | Unknown | 1.3 mg/kg | Oral |
| Subject | Asciminib | Unknown | 2.6 mg/kg | Oral |
| Subject | Bosutinib | Small molecule | — | Oral |
| Subject | Imatinib | Small molecule | — | Oral |
| Subject | Nilotinib | Small molecule | — | Oral |
| Subject | dasatinib anhydrous | Small molecule | — | Oral |